natgillin/translations-raw huggingface dataset:
This shall include the situation where both or one of the parties withdraw from the procedure in accordance with point (a) of Article 9(2) of Directive 2013/11/EU.
To vključuje tudi primere, v katerih sta se obe ali ena od strank umaknili iz postopka v skladu s točko (a) člena 9(2) Direktive 2013/11/EU.
Conclusion of certain disputes and deletion of personal data
Rešitev določenih sporov in izbris osebnih podatkov
A dispute submitted through the ODR platform shall not be processed further in particular where:
Spor, predložen prek platforme za SRS, se ne obravnava naprej, zlasti če:
the respondent party states that it is not willing to use an ADR entity;
nasprotna stranka izjavi, da ni pripravljena uporabiti organa ARS;
the parties fail to agree on an ADR entity to deal with their dispute within 30 calendar days after submission of the electronic complaint form;
se stranki v 30 koledarskih dneh po vložitvi elektronskega obrazca za pritožbe ne dogovorita o organu ARS za obravnavo njunega spora;
the ADR entity agreed on by the parties refuses to deal with the dispute,
organ ARS, o katerem sta se stranki dogovorili, obravnavo spora zavrne,
and shall be considered as concluded.
in se šteje za rešen.
The date of the occurrence of any of the events referred to in points (a) to (c) shall be the date of conclusion of the respective dispute.
Dan katerega koli dogodka iz točk (a) do (c) šteje za datum rešitve zadevnega spora.
The personal data related to the disputes referred to in points (a) to (c) of the first paragraph shall be deleted from the platform at the latest six months after their conclusion.
Osebni podatki, ki se nanašajo na spore iz točk (a) do (c) prvega odstavka, se iz platforme izbrišejo najpozneje šest mesecev po rešitvi teh sporov.
Electronic notification of the list of ADR entities
Elektronska predložitev seznama organov ARS
Competent authorities as defined under point (i) of Article 4(1) of Directive 2013/11/EU, in order to notify the list of ADR entities referred to in Article 20(2) of Directive 2013/11/EU, shall use a standardised electronic form provided by the Commission.
Pristojni organi, kakor so opredeljeni v točki (i) člena 4(1) Direktive 2013/11/EU, za predložitev seznama organov ARS iz člena 20(2) Direktive 2013/11/EU uporabijo standardizirani elektronski obrazec, ki ga zagotavlja Komisija.
The completed standardised electronic form will include the information as referred to in Article 20(2) of Directive 2013/11/EU and the information on the average length of the ADR procedure as referred to in point (d) of Article 9(5) of Regulation (EU) No 524/2013 and point (e) of Article 19(1) of Directive 2013/11/EU.
Izpolnjen standardizirani elektronski obrazec vsebuje informacije iz člena 20(2) Direktive 2013/11/EU in informacije o povprečnem trajanju postopkov ARS, kakor so navedene v točki (d) člena 9(5) Uredbe (EU) št. 524/2013 in točki (e) člena 19(1) Direktive 2013/11/EU.
Feedback system
Sistem povratnih informacij
The ODR platform shall give the possibility to the parties involved in a dispute to give their feedback pursuant to point (g) of Article 5(4) of Regulation (EU) No 524/2013 upon conclusion of the ADR procedure and for six months thereafter.
Platforma za SRS strankam, vpletenim v spor, omogoča, da po zaključku postopka ARS in še šest mesecev po tem roku dajo povratne informacije v skladu s točko (g) člena 5(4) Uredbe (EU) št. 524/2013.
Cooperation between ODR contact points
Sodelovanje med kontaktnimi točkami za SRS
ODR contact points shall provide support to the resolution of disputes relating to complaints submitted through the ODR platform as provided for by Article 7(2) of Regulation (EU) No 524/2013 to the best of their ability.
Kontaktne točke za SRS v skladu s členom 7(2) Uredbe (EU) št. 524/2013 po svojih najboljših močeh zagotavljajo podporo reševanju sporov v zvezi s pritožbami, vloženimi prek platforme za SRS.
ODR advisors shall without delay provide assistance to and exchange information with advisors in other ODR contact points in order to facilitate the performance of their functions listed in Article 7(2) of Regulation (EU) No 524/2013.
Svetovalci za SRS brez odlašanja zagotovijo pomoč svetovalcem v drugih kontaktnih točkah za SRS in si z njimi izmenjajo informacije, da jim olajšajo izvajanje njihovih nalog iz člena 7(2) Uredbe (EU) št. 524/2013.
ODR advisors who have access to information concerning a dispute including personal data shall grant access to this information to advisors in other ODR contact points in so far as it is necessary for the purpose of fulfilling the functions referred to in Article 7(2) of Regulation (EU) No 524/2013.
Svetovalci za SRS, ki imajo dostop do informacij v zvezi s sporom, vključno z osebnimi podatki, odobrijo dostop do teh informacij svetovalcem v drugih kontaktnih točkah za SRS, kolikor je to potrebno za izpolnjevanje nalog iz člena 7(2) Uredbe (EU) št. 524/2013.
OJ L 165, 18.6.2013, p.
UL L 165, 18.6.2013, str.
Following an application from SANOFI-AVENTIS FRANCE submitted pursuant to Article 19(1) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL-cholesterol.
Družba SANOFI-AVENTIS FRANCE je v skladu s členom 19(1) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za pravno zaščito podatkov, Agencija pa je morala pripraviti mnenje o spremembi odobritve zdravstvene trditve v zvezi z estri rastlinskih sterolov in zniževanjem LDL-holesterola v krvi.
That health claim has been authorised, pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, by Commission Regulations (EC) No 983/2009 [2] and (EU) No 384/2010 [3].
Navedena zdravstvena trditev je bila v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 odobrena z uredbama Komisije (ES) št. 983/2009 [2] in (EU) št. 384/2010 [3].
The applicant requested an extension of the conditions of use, as provided for in Regulation (EC) No 983/2009 as amended by Regulation (EU) No 376/2010 [4] and in Regulation (EU) No 384/2010 in its original version, to powder supplements to be diluted in water at a dose of 2 g per day, which would lower blood LDL-cholesterol concentrations by ‘5,4-8,1 %’ after six weeks of daily consumption.
Vlagatelj je zahteval razširitev pogojev uporabe, kot je določeno v Uredbi (ES) št. 983/2009, kakor je bila spremenjena z Uredbo (EU) št. 376/2010 [4], in v Uredbi (EU) št. 384/2010 v prvotni različici, in sicer na prehranska dopolnila v prahu, ki se z odmerkom 2 g dnevno razredčijo v vodi, kar naj bi zmanjšalo koncentracijo LDL-holesterola v krvi za „5,4–8,1 %“ po šestih tednih dnevnega uživanja.
On 21 February 2014, the Commission and the Member States received a scientific opinion from the Authority (Question No EFSA-Q-2013-00595) [5] which concluded that while plant sterols added to foods such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, yoghurts, including low-fat yoghurts, and cheese have been shown consistently to lower blood LDL-cholesterol concentrations in a large number of studies, the effective dose of plant sterols (as powder diluted in water) needed to achieve a given magnitude of effect in a given timeframe, as requested by the applicant, cannot be established with the data provided.
Komisija in države članice so 21. februarja 2014 prejele znanstveno mnenje Agencije (vprašanje št.
In accordance with the second paragraph of Article 16(6) of Regulation (EC) No 1924/2006, the applicant or members of the public may make comments to the Commission on opinions published by the Authority pursuant to the first paragraph of Article 16(6) of that Regulation.
EFSA-Q-2013-00595) [5], ki navaja, da je bilo sicer v številnih študijah dosledno dokazano, da rastlinski steroli, dodani živilom, kot so margarinski namazi, majoneza, solatni prelivi in mlečni izdelki, kot so mleko in jogurti, vključno z jogurti z manj maščobe, ter sir, znižujejo koncentracije LDL-holesterola v krvi, vendar se na podlagi predloženih podatkov ne da določiti efektivne doze rastlinskih sterolov (v obliki prahu, razredčenega v vodi), ki je potrebna za dosego določenega učinka v določenem časovnem okviru, kot je zahteval vlagatelj.
On 14 April 2014, the Commission requested the Authority to respond to the scientific comments received from the applicant according to Article 16(6) of Regulation (EC) No 1924/2006.
V skladu z drugim odstavkom člena 16(6) Uredbe (ES) št. 1924/2006 lahko vlagatelj ali javnost Komisiji predložita pripombe na mnenja, ki jih Agencija objavi v skladu s prvim odstavkom člena 16(6) navedene uredbe.
The comments were related to the scientific evaluation of the Authority on the extension of the conditions of use to plant sterol esters in powder, in particular to the intervention study on which the conclusion of the adopted scientific opinion was based and to a new published meta-analysis which was submitted with the comments.
Komisija je 14. aprila 2014 Agencijo zaprosila, naj odgovori na znanstvene pripombe, ki jih je vlagatelj predložil v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
On 21 May 2014, the Commission received the Authority's response to the comments on the scientific opinion (Question No EFSA-Q-2014-00310) [6] in which the Authority reiterated the conclusion of its scientific opinion (Question No EFSA-Q-2013-00595) with respect to the intervention study.
Te pripombe so se nanašale na znanstveno oceno Agencije o razširitvi pogojev uporabe na estre rastlinskih sterolov v prahu, in sicer zlasti na intervencijsko študijo, na kateri je bil utemeljen sklep sprejetega znanstvenega mnenja, in na novo objavljeno metaanalizo, ki je bila predložena s pripombami.
The Authority added that the new published meta-analysis does not provide additional information for the scientific substantiation of the extension of the conditions of use to plant sterol esters in powder.
Komisija je 21. maja 2014 prejela odgovor Agencije na pripombe na znanstveno mnenje (vprašanje št.
Accordingly, as under the requested conditions of use the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
EFSA-Q-2014-00310) [6], v katerem je Agencija ponovno potrdila sklep iz svojega znanstvenega mnenja (vprašanje št.
Following an application from Jemo-pharm A/S submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of CranMax® and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract (Question No EFSA-Q-2013-00649) [7].
EFSA-Q-2013-00595), kar se tiče intervencijske študije.
The claim proposed by the applicant was worded as follows: ‘Prevent adhesion of E. coli to the uroepithelial cells in women which is a risk factor for developing urinary tract infections’.
Agencija je še dodala, da v novo objavljeni metaanalizi ni dodatnih informacij, ki bi omogočile znanstveno utemeljitev razširitve pogojev uporabe na estre rastlinskih sterolov v prahu.
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship has not been established between the consumption of CranMax® and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract.
Ker pod zahtevanimi pogoji uporabe zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Družba Jemo-pharm A/S je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za pravno zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom CranMax®, ki naj bi s preprečevanjem zadrževanja nekaterih bakterij v urinskem traktu zmanjšal tveganje za okužbo sečil (vprašanje št.
The comments received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
EFSA-Q-2013-00649) [7].
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Vlagatelj je predlagal naslednjo trditev: „Preprečuje zadrževanje bakterij E. coli na urotelijskih celicah pri ženskah, ki je dejavnik tveganja za razvoj okužbe sečil“.
HAS ADOPTED THIS REGULATION:
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem CranMax® in zmanjšanjem tveganja za okužbo sečil s preprečevanjem zadrževanja nekaterih bakterij v urinskem traktu ni utemeljena.
Article 1
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Pri določanju ukrepov iz te uredbe so se upoštevale pripombe, ki jih je Komisija prejela v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
Article 2
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za rastline, živali, hrano in krmo –
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
SPREJELA NASLEDNJO UREDBO:
Done at Brussels, 1 July 2015.
Zdravstvene trditve iz Priloge k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children's development and health (OJ L 277, 22.10.2009, p. 3).
V Bruslju, 1. julija 2015
Commission Regulation (EU) No 384/2010 of 5 May 2010 on the authorisation and refusal of authorisation of certain health claims made on foods and referring to the reduction of disease risk and to children's development and health (OJ L 113, 6.5.2010, p. 6).
Za Komisijo
Commission Regulation (EU) No 376/2010 of 3 May 2010 amending Regulation (EC) No 983/2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children's development and health (OJ L 111, 4.5.2010, p. 3).
Predsednik
ANNEX
Uredba Komisije (EU) št. 376/2010 z dne 3. maja 2010 o spremembi Uredbe (ES) št. 983/2009 o odobritvi in zavrnitvi odobritve nekaterih zdravstvenih trditev na živilih, ki se nanašajo na zmanjšanje tveganja za bolezni ter na razvoj in zdravje otrok (UL L 111, 4.5.2010, str. 3).
Application — Relevant provisions of Regulation (EC) No 1924/2006
Zavrnjene zdravstvene trditve
Modification, pursuant to Article 19, of an Article 14(1)(a) health claim referring to a reduction of a disease risk.
Referenčno mnenje Evropske agencije za varnost hrane
Plant sterol esters
Sprememba, v skladu s členom 19, zdravstvene trditve po členu 14(1)(a), ki se nanaša na zmanjšanje tveganja za nastanek bolezni.
Plant sterol esters presented as food supplement in powder sachet have been shown to lower/reduce blood cholesterol.
Estri rastlinskih sterolov
High cholesterol is a risk factor in the development of coronary heart disease.
Estri rastlinskih sterolov v obliki prehranskega dopolnila v vrečicah s praškom dokazano znižujejo holesterol v krvi.
Article 14(1)(a) health claim referring to a reduction of a disease risk.
Povišan holesterol je dejavnik tveganja za razvoj koronarne bolezni srca.
Prevent adhesion of E. coli to the uroepithelial cells in women which is a risk factor for developing urinary tract infections.
Zdravstvena trditev po členu 14(1)(a), ki se nanaša na zmanjšanje tveganja za nastanek bolezni.
Commission Implementing Regulation (EU) 2015/1053
Izvedbena uredba Komisije (EU) 2015/1053
concerning the authorisation of the preparation of Enterococcus faecium DSM 10663/NCIMB 10415 as a feed additive for calves for rearing, piglets, chickens for fattening, turkeys for fattening, cats and dogs and amending Regulations (EC) No 1259/2004, (EC) No 255/2005, (EC) No 1200/2005 and (EC) No 1520/2007 (holder of authorisation Chevita Tierarzneimittel-GmbH)
o izdaji dovoljenja za pripravek iz Enterococcus faecium DSM 10663/NCIMB 10415 kot krmni dodatek za teleta za vzrejo, pujske, piščance za pitanje, purane za pitanje, mačke in pse ter o spremembi uredb (ES) št. 1259/2004, (ES) št. 255/2005, (ES) št. 1200/2005 in (ES) št. 1520/2007 (imetnik dovoljenja je družba Chevita Tierarzneimittel-GmbH)
The preparation of Enterococcus faecium DSM 10663/NCIMB 10415 was authorised without a time limit in accordance with Directive 70/524/EEC as a feed additive for chickens for fattening by Commission Regulation (EC) No 1259/2004 [3], for calves by Commission Regulation (EC) No 255/2005 [4], for piglets by Commission Regulation (EC) No 1200/2005 [5], for turkeys for fattening and dogs by Commission Regulation (EC) No 1520/2007 [6].
Pripravek iz Enterococcus faecium DSM 10663/NCIMB 10415 je bil v skladu z Direktivo 70/524/EGS brez časovne omejitve dovoljen kot krmni dodatek za piščance za pitanje z Uredbo Komisije (ES) št. 1259/2004 [3], za teleta z Uredbo Komisije (ES) št. 255/2005 [4], za pujske z Uredbo Komisije (ES) št. 1200/2005 [5], za purane za pitanje in pse pa z Uredbo Komisije (ES) št. 1520/2007 [6].
That preparation was subsequently entered in the Register of feed additives as an existing product, in accordance with Article 10(1) of Regulation (EC) No 1831/2003.
Navedeni pripravek je bil v skladu s členom 10(1) Uredbe (ES) št. 1831/2003 naknadno vpisan v register krmnih dodatkov kot obstoječi proizvod.
In accordance with Article 10(2) of Regulation (EC) No 1831/2003 in conjunction with Article 7 of that Regulation, an application was submitted for the re-evaluation of the preparation of Enterococcus faecium DSM 10663/NCIMB 10415 as a feed additive for calves for rearing, piglets, chickens for fattening, turkeys for fattening and dogs and, in accordance with Article 7 of that Regulation, for a new use for cats, requesting that additive to be classified in the additive category ‘zootechnical additives’.
V skladu s členom 10(2) Uredbe (ES) št. 1831/2003 v povezavi s členom 7 navedene uredbe je bil predložen zahtevek za ponovno oceno pripravka Enterococcus faecium DSM 10663/NCIMB 10415 kot krmnega dodatka za teleta za vzrejo, pujske, piščance za pitanje, purane za pitanje in pse ter, v skladu s členom 7 navedene uredbe, za novo uporabo za mačke in za uvrstitev navedenega dodatka v kategorijo dodatkov „zootehnični dodatki“.
The European Food Safety Authority (‘the Authority’) concluded in its opinions of 4 March 2014 [7] and 21 May 2014 [8] that, under the proposed conditions of use, the preparation of Enterococcus faecium DSM 10663/NCIMB 10415 does not have an adverse effect on animal health, human health or the environment.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v mnenjih z dne 4. marca 2014 [7] in 21. maja 2014 [8] ugotovila, da pripravek iz Enterococcus faecium DSM 10663/NCIMB 10415 pod predlaganimi pogoji uporabe nima škodljivega učinka na zdravje živali in ljudi ali na okolje.
The Authority further concluded that the use of that preparation has the potential to improve zootechnical performance of calves for rearing, piglets (suckling and weaned), chickens for fattening and turkeys for fattening.
Poleg tega je Agencija ugotovila, da lahko uporaba navedenega pripravka izboljša proizvodne lastnosti telet za vzrejo, pujskov (sesnih in odstavljenih), piščancev za pitanje in puranov za pitanje.
Since small but significant effects on faecal quality were observed by the EFSA in cats and dogs, it is considered sufficient to confirm the efficacy in these species.
Agencija je pri mačkah in psih opazila sicer majhne, a bistvene učinke na fekalno kakovost, ki so bili obravnavani kot zadostni za potrditev učinkovitosti pri teh vrstah.
The assessment of the preparation of Enterococcus faecium DSM 10663/NCIMB 10415 shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Ocena pripravka iz Enterococcus faecium DSM 10663/NCIMB 10415 je pokazala, da so pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003 izpolnjeni.
As a consequence of the granting of a new authorisation under Regulation (EC) No 1831/2003, Regulations (EC) No 1259/2004, (EC) No 255/2005, (EC) No 1200/2005 and (EC) No 1520/2007 should be amended accordingly.
Zaradi izdaje novega dovoljenja v skladu z Uredbo (ES) št. 1831/2003 bi bilo treba ustrezno spremeniti uredbe (ES) št. 1259/2004, (ES) št. 255/2005, (ES) št. 1200/2005 in (ES) št. 1520/2007.
The preparation specified in the Annex, belonging to the additive category ‘zootechnical additives’ and to the functional group ‘gut flora stabilisers’, is authorised as an additive in animal nutrition, subject to the conditions laid down in that Annex.
Pripravek iz Priloge, ki spada v kategorijo dodatkov „zootehnični dodatk“ in funkcionalno skupino „stabilizatorji mikroflore“, se dovoli kot dodatek v prehrani živali v skladu s pogoji iz navedene priloge.
Amendments to Regulation (EC) No 1259/2004
Spremembi Uredbe (ES) št. 1259/2004
Regulation (EC) No 1259/2004 is amended as follows:
Uredba (ES) št. 1259/2004 se spremeni:
Amendment to Regulation (EC) No 255/2005
Sprememba Uredbe (ES) št. 255/2005
In Annex I to Regulation (EC) No 255/2005, the entry on E 1707, Enterococcus faecium DSM 10663/NCIMB 10415, is deleted.
V Prilogi I k Uredbi (ES) št. 255/2005 se črta vnos za E 1707, Enterococcus faecium DSM 10663/NCIMB 10415.
Amendment to Regulation (EC) No 1200/2005
Sprememba Uredbe (ES) št. 1200/2005
In Annex II to Regulation (EC) No 1200/2005, the entry on E 1707, Enterococcus faecium DSM 10663/NCIMB 10415, is deleted.
V Prilogi II k Uredbi (ES) št. 1200/2005 se črta vnos za E 1707, Enterococcus faecium DSM 10663/NCIMB 10415.
Amendments to Regulation (EC) No 1520/2007
Spremembe Uredbe (ES) št. 1520/2007
Articles 2 and 3 are deleted.
člena 2 in 3 se črtata;
The preparation specified in the Annex and feed containing that preparation, which are produced and labelled before 22 January 2016 in accordance with the rules applicable before 22 July 2015 may continue to be placed on the market and used until the existing stocks are exhausted if they are intended for calves, piglets, chickens for fattening and turkeys for fattening.
Pripravek iz Priloge in krma, ki vsebuje navedeni pripravek, proizvedena in označena pred 22. januarjem 2016 v skladu s pravili, ki se uporabljajo pred 22. julijem 2015, se lahko še naprej dajeta na trg in uporabljata do porabe obstoječih zalog, če sta namenjena za teleta, pujske, piščance za pitanje in purane za pitanje.
The preparation specified in the Annex and feed containing that preparation, which are produced and labelled [for dogs] before 22 July 2017 in accordance with the rules applicable before 22 July 2015 may continue to be placed on the market and used until the existing stocks are exhausted if they are intended for dogs.
Pripravek iz Priloge in krma, ki vsebuje navedeni pripravek, proizvedena in označena [za pse] pred 22. julijem 2017 v skladu s pravili, ki se uporabljajo pred 22. julijem 2015, se lahko še naprej dajeta na trg in uporabljata do porabe obstoječih zalog, če sta namenjena za pse.
Commission Regulation (EC) No 1259/2004 of 8 July 2004 concerning the permanent authorisation of certain additives already authorised in feedingstuffs (OJ L 239, 9.7.2004, p. 8).
Uredba Komisije (ES) št. 1259/2004 z dne 8. julija 2004 o trajnem dovoljenju določenih v krmi že dovoljenih dodatkov (UL L 239, 9.7.2004, str. 8).